Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

分组1 - Editas Medicine reported a quarterly loss of $0.28 per share, better than the Zacks Consensus Estimate of a loss of $0.38, and an improvement from a loss of $0.75 per share a year ago, resulting in an earnings surprise of +26.32% [1] - The company posted revenues of $7.54 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 365.62%, compared to revenues of $0.06 million in the same quarter last year [2] - Editas shares have increased approximately 94.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $5.52 million, and for the current fiscal year, it is -$2.12 on revenues of $15.38 million [7] - The Medical - Biomedical and Genetics industry, to which Editas belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]